Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Increased by Teacher Retirement System of Texas

Teacher Retirement System of Texas raised its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 42.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,963 shares of the company’s stock after buying an additional 9,769 shares during the period. Teacher Retirement System of Texas’ holdings in Vaxcyte were worth $2,698,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in PCVX. Whipplewood Advisors LLC bought a new stake in shares of Vaxcyte during the 4th quarter worth $28,000. Smartleaf Asset Management LLC boosted its position in shares of Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after purchasing an additional 260 shares during the period. Blue Trust Inc. increased its stake in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after purchasing an additional 371 shares in the last quarter. Assetmark Inc. raised its holdings in Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after buying an additional 775 shares during the period. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in Vaxcyte during the third quarter valued at about $92,000. 96.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PCVX has been the topic of several analyst reports. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $147.50.

Insider Activity

In other news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now directly owns 7,175 shares of the company’s stock, valued at $610,664.25. This trade represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total value of $669,280.00. Following the transaction, the chief operating officer now owns 205,695 shares in the company, valued at approximately $17,208,443.70. This represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 46,250 shares of company stock valued at $3,840,018 over the last 90 days. 3.10% of the stock is owned by company insiders.

Vaxcyte Stock Down 2.6 %

Shares of PCVX stock opened at $71.90 on Wednesday. The company has a market capitalization of $9.26 billion, a P/E ratio of -15.63 and a beta of 1.02. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The firm has a 50-day moving average price of $81.14 and a 200 day moving average price of $93.33.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. As a group, research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.